| Primary information |
|---|
| sequence ID | Seq_1779 |
| Peptide sequence | EGDFLAEGGGVR |
| CancerPDF_ID | CancerPDF_ID5, CancerPDF_ID643, CancerPDF_ID1023, CancerPDF_ID1228, CancerPDF_ID8505, CancerPDF_ID9662, CancerPDF_ID11424, CancerPDF_ID12686, |
| PMID | 16896061,19795908,16395409,21136997,23667664,21533267,26992070,25168216 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Serum,Serum,Serum,Serum |
| M/Z | 1206.57,603.79,1206.57,1205.56767,1205.57,603.77,1205.5677,NA |
| Charge | 1,2,1,1,1,2,NA,NA |
| Mass (in Da) | 1206.58,NA,NA,NA,1207.29,NA,1206.578783,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA,1205.58 |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS,LC-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,NA,1.49,FDR 1 %,NA |
| CancerPDF_ID | CancerPDF_ID5, CancerPDF_ID643, CancerPDF_ID1023, CancerPDF_ID1228, CancerPDF_ID8505, CancerPDF_ID9662, CancerPDF_ID11424, CancerPDF_ID12686, |
| p-Value | 1.00E-05,NA,1.31E-09,NA,NA,8.17E-27,NA,8.86E_04 |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT,MASCOT,SEQUEST and Maxquant,MASCOT |
| Length | 12,12,12,12,12,12,12,12 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Melanoma,Renal cell carcinaoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database,SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples,"30 RCC patients and 30 healthy controls for training dataset and 6 RCC patients, 6 control in independent validation dataset" |
| Regulation | Differentially expressed between cancer vs normal samples,NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.5, 0.44 and 0.69 in prostate, bladder and breast cancer respectively",NA,NA,Differentially expressed between Lung cancer vs control,"Present in 7 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples.",Upregulated in cancer v/s Normal |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,na,Independent validation |
| Sensitivity | 95% on independent dataset,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA,NA,NA,100 % (for 19 peptide signatures) |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,0.802,NA,AUC : 0.730 |
| Peptide Atlas | PeptideAtlas |
| IEDB | 462581
|